Suhfr 2016 ISA Prsdfdtail Page 3, Bullet 2; Image
From Molecule to Medicine, p4, Figure
NCT02510261, Page 2, Inclusion Criteria, Bullet 1
Durbqqdwey 2015, p439, §2, ¶3, ln1-6
Hawkfsins 2015 p3, §2, ¶2, ln1-4
Sipfdfse 2014, p223, sec2, ¶4, ln3-10
Autosomal Dominant Inheritance_NIH, Page 1, Para 5, Line 1; Para 7, Line 1
Familial Transthyretin Amyloidosis, Page 2, Para 2, Bullet 1
Hannas 2014, p51, Table 1
Carbs, Proteins, and Fats 2017, Page 1, Para 1, Bullets 1-2; Page 6, Para 5, Lines 1-2
Fieffsdfer 2011, Page 55, (Introduction) Para 1, Line 1; Page 56, Col 1, Para 2, Lines 1-4; Page 58, Col 2, Para 1, Lines 1-2
Domsssuñoz 2007, Page 116, Col 2, Para 1, Lines 1-2 & 20-22; Page 117, Col 1, Para 2, Lines 1-8
Dumy 2004, Page 1352, Table 3
Kelefer 2005, Page 8, Col 2, ¶3, ln16-18; ¶5, ln1-8; Page 9, Figure 8
Kelefer 2005, page 8, col 2, para 3, lines 16-18; para 5, lines 1-8; page 9, figure 8
Kelefer 2005, Page vi8, Col 2, Para 3, Lines 16-18; Para 5, Lines 1-8; Page 9, fig8
Kelefer 2005, pg 8, c2, Para 3, Lines 16-18; Para 5, Lines 1-8; pg 9, Fig 8
Fseffmark 2005 Chapter 4, Page 53, Para 5, Lines 1-3; Page 54, Para 3, Lines 1-4; Lines 7-11
Protein Malabsorption linked to EPI:
Evsefns 1966, Page 594, Para 1, Lines 1-3, Para 2, Lines 1-8
Bseftz 2007, Page 50, Col 1, Para 1
Msefsefck 2016 BOS, Page 2, Para 1, Lines 1-3
Loff 2012 Chapter 295, Page 1, Para 34, Lines 1-4; Para 35, Lines 1-3; Para 38, Lines 1-3; Para 40, Lines 1-3
Ssssfds 2010 Chapter 111, Page 1952, Col 2, Para 3, Lines 1-2; Lines 11-14; Page 1953, Col 1, Para 2, Lines 1-13; Para 4, Lines 1-4; Col 2, Para 1, Lines 1-2; Para 2, Lines 1-10; Para 3, Lines 1-3
Lisssein 2012 Chapter 143, Page 914, Col 1, Para 10, Line 3; Col 2, Para 1, Lines 1-4; Page 916, Col 2, Para 2, Lines 1-2; Page 920, Col 2, Para 4, Line 6
Logo 2012 Chapter 295, Page 1, Para 23, Lines 1-2; Para 24, Lines 1-3; Para 25, Lines 1-4; Page 5, Table 295-4
Durbqqdwey 2015, p439, §2, ¶3, ln1-6
Hawkfsins 2015 p3, §2, ¶2, ln1-4
Sipfdfse 2014, p223, sec2, ¶4, ln3-10
Durbqqdwey 2015, p439, § 2, ¶3, ln1-6
Hawkfsins 2015 pg3, §2, ¶2, ln1-4
Sipfdfse 2014, pg223, sec2, ¶4, ln3-10
Gsdfeswek 2006, Page 1313, Col 1, Para 1, Lines 1-10; Col 2, Para 1, Lines 2-3
Dofdguez-duño 2007, pg 116, §intro, col1, ¶1, ln1-12
Etsdfd 2001, p687, c2, ¶3, ln1-8; p688, c1, ¶2, ln12-20
Ksdfsdler 2005, p vi21, c2, ¶6, ln1-4
Wdfgt 2007, pg1569, col2, ¶ 4, ln1-4; ln15-19
DOF IMS NPA and NSP Data, Page 4, Bullet 1
DOF #1 Claim Weekly IMS Data
Autosomal Dominant Inheritance_NIH, Page 1, Para 5, Line 1; Para 7, Line 1
Familial Transthyretin Amyloidosis, Pg 2, Para 2, Bullet 1
Hannas 2014, p51, Table 1
Carbs, Proteins, and Fats 2017, Page 1, Para 1, Bullets 1-2; Page 6, Para 5, Lines 1-2
Fieffsdfer 2011, Page 55, (Introduction) Para 1, Line 1; Page 56, Col 1, Para 2, Lines 1-4; Page 58, Col 2, Para 1, Lines 1-2
Domsssuñoz 2007, Page 116, Col 2, Para 1, Lines 1-2 & 20-22; Page 117, Col 1, Para 2, Lines 1-8
Dumy 2004, Page 1352, Table 3
Kelefer 2005, Page vi8, Col 2, Para 3, Lines 16-18; Para 5, Lines 1-8; Page vi9, Figure 8
Fseffmark 2005 Chapter 4, Page 53, Para 5, Lines 1-3; Page 54, Para 3, Lines 1-4; Lines 7-11
Protein Malabsorption linked to EPI:
Evsefns 1966, Page 594, Para 1, Lines 1-3, Para 2, Lines 1-8
Bseftz 2007, Page 50, Col 1, Para 1
Msefsefck 2016 BOS, Page 2, Para 1, Lines 1-3
Loff 2012 Chapter 295, Page 1, Para 34, Lines 1-4; Para 35, Lines 1-3; Para 38, Lines 1-3; Para 40, Lines 1-3
Ssssfds 2010 Chapter 111, Page 1952, Col 2, Para 3, Lines 1-2; Lines 11-14; Page 1953, Col 1, Para 2, Lines 1-13; Para 4, Lines 1-4; Col 2, Para 1, Lines 1-2; Para 2, Lines 1-10; Para 3, Lines 1-3
Lisssein 2012 Chapter 143, Page 914, Col 1, Para 10, Line 3; Col 2, Para 1, Lines 1-4; Page 916, Col 2, Para 2, Lines 1-2; Page 920, Col 2, Para 4, Line 6
Logo 2012 Chapter 295, Page 1, Para 23, Lines 1-2; Para 24, Lines 1-3; Para 25, Lines 1-4; Page 5, Table 295-4
Gsdfeswek 2006, Page 1313, Col 1, Para 1, Lines 1-10; Col 2, Para 1, Lines 2-3
Dofdguez-duño 2007, pg 116, §intro, col1, ¶1, ln1-12
Etsdfd 2001, p687, c2, ¶3, ln1-8; p688, c1, ¶2, ln12-20
Ksdfsdler 2005, p vi21, c 2, ¶6, ln1-4
Wdfgt 2007, pg 1569, col 2, ¶4, ln1-4; ln15-19
DOF IMS NPA and NSP Data, Page 4, Bullet 1
DOF #1 Claim Weekly IMS Data
Naik 2013 , Page 1, Col 1, Methods
AKEHKJD PI 2016 p3, Black Box Warning, SERIOUS INFECTIONS, ¶1, l1-4
AKEHKJD PI 2016 pg 3, Black Box Warning, SERIOUS INFECTIONS, ¶ 1, ln1-4
AKEHKJD PI 2006 pg3, Black Box Warning, SERIOUS INFECTIONS, ¶1, lines 1-11
LLLLJAJ PI 2006 pg10, ¶5, l5-7; p11, ¶1 l1-2
LLpLJAJ PI 206 pg10, para5, l5-7; p11, para1 lines1-2
LpvbJAJ PI 2016 p10, para 5, l5-7; p11, para1 l1-2
LLLLJAJ PI 2016 p10, ¶ 5, l5-7; p11, ¶1 l1-2
Daivk 2013 , Page 1, Col 1, Methods
Furman 2014, Page 4, Table 1
CDER, Page 37, Table 9
Furman Supp 2014, Page 3, Table S1
Gopal 2014, Page 1, Methods, Lines 5-6; Page 3, Col 2, Para 2
Burmester 2013 p517, §2, ¶4, l1-7; p518, §1, ¶5, l1-2;
AKEHKJD PI 2016 p3, Black Box Warning, SERIOUS INFECTIONS, ¶1, l1-4
QQdsfter 2003, pg 107, §1, ¶3, l1-6
fsdfnt 2007, p114, Table IV
Cavid PI 2016, §2.3, ¶2, ln1-2; §16.1, ¶1, ln1-3
van der Linden 2002, pg530, col1, ¶2, ln1-4; pg532, col1, ¶3, ln3-11; col2, ¶1, ln1-6
Fanikos 2007, pg2039, col2, ¶3, ln1-15; col3, ¶1, ln1-16; ¶3, ln5-20
ASHP Guidelines 2013, pg485, col1, ¶3, ln6-13; ¶5, ln1-8
Joint Commission 2015, pgMM-18, §MM.05.01.11 C4
ISMP 2016, pg8, §Compounding, bullet 1
Fabio 1997, pg98, col1, ¶5, ln5-7; col2, ¶3, ln1-3; pg99, col2, ¶2, ln1-6
Cavid PI 2016, §14, ¶1, ln1-12
Generic PI 2006, pg2, §Dosage and Administration-Preparation, ¶5, ln1-2